Lymphoma, Non-Hodgkin, Familial disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

NHL MCID: LYM143 MIFTS: 74	Lymphoma, Non-Hodgkin, Familial (NHL) Categories: Blood diseases, Cancer diseases, Genetic diseases, Immune diseases, Rare diseases	Data Licensing For inquiries, contact: [email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Lymphoma, Non-Hodgkin, Familial

MalaCards integrated aliases for Lymphoma, Non-Hodgkin, Familial:

Name: Lymphoma, Non-Hodgkin, Familial ⁵⁷ ²⁸ ⁵ ³⁶ ³⁸

Non-Hodgkin Lymphoma ⁵⁷ ¹¹ ⁵⁸ ⁷⁵ ²⁸ ⁵ ¹⁴

Lymphoma, Non-Hodgkin ⁵⁷ ¹² ⁴³ ⁷¹

Nhl ⁵⁷ ⁵⁸ ⁷³

Lymphoma, Non-Hodgkin, Somatic ⁵⁷

Lymphoma, Follicular, Somatic ⁵⁷

Familial Non-Hodgkin Lymphoma ⁷³

Follicular Lymphoma, Somatic ⁵

Lymphoma Non-Hodgkins ⁵³

Non-Hodgkins Lymphoma ¹⁶

Lymphosarcoma ¹⁴

Characteristics:

Prevelance:

Non-Hodgkin Lymphoma: 1-5/10000 (Europe) ⁵⁸

Age Of Onset:

Non-Hodgkin Lymphoma: Adolescent,Adult,Childhood,Elderly,Infancy ⁵⁸

Classifications:

MalaCards categories:
Global: Genetic diseases Cancer diseases Rare diseases
Anatomical: Blood diseases Immune diseases

See all MalaCards categories (disease lists)

ICD10: ³¹

Neoplasms

Malignant neoplasms, stated or presumed to be primary, of lymphoid, haematopoietic and related tissue

Other and unspecified types of non-Hodgkin lymphoma

Non-Hodgkin lymphoma, unspecified

Other specified types of non-Hodgkin lymphoma

Orphanet: ⁵⁸

Rare haematological diseases

External Ids:

Disease Ontology ¹¹ DOID:0060060

OMIM® ⁵⁷ 605027

MeSH ⁴³ D008228

ICD10 ³¹ C85.7 C85.9

MESH via Orphanet ⁴⁴ D008228

UMLS via Orphanet ⁷² C0024305

Orphanet ⁵⁸ ORPHA547

MedGen ⁴⁰ C0024305 C4721532

SNOMED-CT via HPO ⁶⁹ 115244002 118600007 188676008 more

EFO ¹⁶ EFO_0005952

UMLS ⁷¹ C0024305

Sources

Summaries for Lymphoma, Non-Hodgkin, Familial

UniProtKB/Swiss-Prot: ⁷³ Cancer that starts in cells of the lymph system, which is part of the body's immune system. NHLs can occur at any age and are often marked by enlarged lymph nodes, fever and weight loss.

MalaCards based summary: Lymphoma, Non-Hodgkin, Familial, also known as non-hodgkin lymphoma, is related to lymphoma and follicular lymphoma. An important gene associated with Lymphoma, Non-Hodgkin, Familial is CASP10 (Caspase 10), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Dacarbazine and Morphine have been mentioned in the context of this disorder. Affiliated tissues include Blood, and related phenotypes are lymphoma and Synthetic lethal with MLN4924 (a NAE inhibitor)

Disease Ontology: ¹¹ A lymphoma that is characterized as any kind of lymphoma except Hodgkin's lymphoma.

Orphanet: ⁵⁸ A heterogeneous group of malignant tumors of the lymphoid system.

Wikipedia: ⁷⁵ Non-Hodgkin lymphoma (NHL), also known as non-Hodgkin's lymphoma, is a group of blood cancers that... more...

More information from OMIM: 605027

Sources

Related Diseases for Lymphoma, Non-Hodgkin, Familial

Diseases related to Lymphoma, Non-Hodgkin, Familial via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1253)

#	Related Disease	Score	Top Affiliating Genes
1	lymphoma	34.6	TP53 TNFRSF8 MYD88 MYC IRF4 EZH2
2	follicular lymphoma	34.1	TP53 PIK3CA MYC IRF4 EZH2 BCL6
3	mantle cell lymphoma	34.0	TP53 TNFRSF8 MYD88 MYC IRF4 EZH2
4	lymphoma, hodgkin, classic	34.0	TP53 TNFRSF8 IRF4 BCL6 BCL2
5	b-cell lymphoma	33.9	TP53 TNFRSF8 MYD88 MYC IRF4 EZH2
6	leukemia, chronic lymphocytic	33.9	TP53 TNFRSF8 PRF1 NRAS MYD88 MYC
7	burkitt lymphoma	33.9	TP53 TNFRSF8 MYC IRF4 BCL6 BCL2
8	diffuse large b-cell lymphoma	33.8	TNFRSF8 MYD88 MYC IRF4 EZH2 BCL6
9	lymphoma, mucosa-associated lymphoid type	33.7	TP53 TNFRSF8 MYD88 MYC IRF4 BCL6
10	angioimmunoblastic t-cell lymphoma	33.2	TNFRSF8 RHOA IRF4 BCL6
11	plasmablastic lymphoma	33.2	TNFRSF8 MYC IRF4 BCL6
12	gastric lymphoma	33.2	TNFRSF8 IRF4 BCL6 BCL2 BCL10
13	mature t-cell and nk-cell lymphoma	33.1	TP53 TNFRSF8 MYC BCL6 BCL2
14	composite lymphoma	33.1	TNFRSF8 BCL6 BCL2
15	high-grade b-cell lymphoma double-hit/triple-hit	33.0	MYC IRF4 EZH2 BCL6 BCL2
16	common variable immunodeficiency	32.8	TP53 TNFRSF8 IRF4 BCL2
17	marginal zone b-cell lymphoma	32.7	TNFRSF8 MYD88 MYC IRF4 BCL6 BCL2
18	primary cutaneous gamma-delta t-cell lymphoma	32.7	TNFRSF8 PRF1
19	myeloma, multiple	32.7	TP53 TNFRSF8 PIK3CA NRAS MYD88 MYC
20	leukemia, acute myeloid	32.6	TP53 TNFRSF8 PRF1 PIK3CA NRAS MYC
21	leukemia	32.5	TP53 NRAS MYC BRAF BCL2 BCL10
22	acquired immunodeficiency syndrome	32.5	TP53 MYC BCL6 BCL2 B2M
23	lymphoproliferative syndrome	32.4	TNFRSF8 PRF1 NRAS CASP10 BCL6 BCL2
24	leukemia, acute lymphoblastic	32.4	TP53 MYC IRF4 BCL6 BCL2
25	chronic lymphocytic leukemia/small lymphocytic lymphoma	32.3	TP53 TNFRSF8 BCL6 BCL2
26	primary mediastinal b-cell lymphoma	32.3	TNFRSF8 MYC IRF4 BCL6 BCL2
27	lymphoblastic lymphoma	32.2	TNFRSF8 BCL6 BCL2
28	peripheral t-cell lymphoma	32.2	TP53 TNFRSF8 BCL6 BCL2
29	reticulosarcoma	32.2	TNFRSF8 MYC BCL6 BCL2 B2M
30	central nervous system lymphoma	32.1	TNFRSF8 MYD88 MYC IRF4 BCL6 BCL2
31	lymphoplasmacytic lymphoma	32.1	MYD88 IRF4 BCL6 BCL2 B2M
32	renal cell carcinoma, nonpapillary	32.1	TP53 RHOA PIK3CA NRAS MYC MAP2K1
33	peripheral nervous system disease	32.1	TP53 TNFRSF8 RHOA NRAS MYC MAP2K1
34	waldenstroem's macroglobulinemia	32.0	MYD88 IRF4 B2M
35	breast lymphoma	32.0	TNFRSF8 IRF4 BCL6 BCL2
36	t-cell acute lymphoblastic leukemia	32.0	TNFRSF8 MYC IRF4 BCL2 BCL10
37	myelodysplastic syndrome	32.0	TP53 NRAS MYC EZH2 BCL2
38	bone lymphoma	32.0	TNFRSF8 IRF4 BCL6 BCL2
39	hepatitis b	32.0	PIK3CA MYD88 MYC BCL2
40	adult t-cell leukemia/lymphoma	32.0	TP53 TNFRSF8 MYC IRF4 BCL2
41	macroglobulinemia	31.9	TP53 MYD88 BCL2
42	lymphatic system disease	31.9	TP53 TNFRSF8 MYC IRF4 BCL6 BCL2
43	skin melanoma	31.9	TP53 PIK3CA NRAS MYC MAP2K1 EZH2
44	leukemia, chronic myeloid	31.9	TP53 NRAS MYC IRF4 BRAF BCL2
45	gastric cancer	31.8	TP53 RHOA PIK3CA NRAS MYC MAP2K1
46	melanoma	31.8	TP53 RHOA PIK3CA NRAS MYC MAP2K1
47	lymphoma aids related	31.8	MYC BCL6
48	pancreatic cancer	31.8	TP53 RHOA PRF1 PIK3CA MYC MAP2K1
49	testicular lymphoma	31.8	TNFRSF8 MYD88 IRF4 BCL6 BCL2
50	skin carcinoma	31.8	TP53 NRAS MYC BCL2

Graphical network of the top 20 diseases related to Lymphoma, Non-Hodgkin, Familial:

Sources

Symptoms & Phenotypes for Lymphoma, Non-Hodgkin, Familial

Human phenotypes related to Lymphoma, Non-Hodgkin, Familial:

³⁰

#	Description	HPO Frequency	Orphanet Frequency	HPO Source Accession
1	lymphoma ³⁰			HP:0002665

Clinical features from OMIM®:

605027 (Updated 08-Dec-2022)

GenomeRNAi Phenotypes related to Lymphoma, Non-Hodgkin, Familial according to GeneCards Suite gene sharing:

²⁵

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Synthetic lethal with MLN4924 (a NAE inhibitor)	GR00250-A-1	9.74	BCL10 MYD88 RAD54L
2	Synthetic lethal with MLN4924 (a NAE inhibitor)	GR00250-A-2	9.74	BCL10 MYD88 RAD54B RAD54L RHOA TP53
3	Synthetic lethal with MLN4924 (a NAE inhibitor)	GR00250-A-3	9.74	RAD54B RAD54L TP53

MGI Mouse Phenotypes related to Lymphoma, Non-Hodgkin, Familial:

⁴⁵ (show all 19)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	homeostasis/metabolism	MP:0005376	10.43	B2M BCL2 BCL6 BRAF EZH2 IRF4
2	endocrine/exocrine gland	MP:0005379	10.37	B2M BCL10 BCL2 BCL6 BRAF EZH2
3	neoplasm	MP:0002006	10.36	B2M BCL2 BRAF EZH2 IRF4 MAP2K1
4	growth/size/body region	MP:0005378	10.36	B2M BCL2 BCL6 BRAF EZH2 IRF4
5	nervous system	MP:0003631	10.34	B2M BCL10 BCL2 BRAF EZH2 MAP2K1
6	cellular	MP:0005384	10.33	B2M BCL10 BCL2 BCL6 BRAF EZH2
7	normal	MP:0002873	10.23	BCL6 BRAF EZH2 MAP2K1 MYC NRAS
8	immune system	MP:0005387	10.22	B2M BCL10 BCL2 BCL6 BRAF EZH2
9	embryo	MP:0005380	10.18	BCL10 BCL2 BRAF EZH2 MAP2K1 MYC
10	digestive/alimentary	MP:0005381	10.16	B2M BCL2 BRAF EZH2 MAP2K1 MYC
11	liver/biliary system	MP:0005370	10.15	B2M BCL6 BRAF MYC MYD88 NRAS
12	adipose tissue	MP:0005375	10.14	BCL2 BCL6 BRAF IRF4 MYC MYD88
13	no phenotypic analysis	MP:0003012	10.11	BCL6 EZH2 MYC MYD88 NRAS PIK3CA
14	cardiovascular system	MP:0005385	10.11	B2M BCL2 BCL6 BRAF EZH2 MAP2K1
15	hematopoietic system	MP:0005397	10.06	B2M BCL10 BCL2 BCL6 BRAF EZH2
16	reproductive system	MP:0005389	10	B2M BCL2 BCL6 BRAF EZH2 MAP2K1
17	craniofacial	MP:0005382	9.98	BCL2 BRAF EZH2 MAP2K1 MYC NRAS
18	mortality/aging	MP:0010768	9.86	B2M BCL10 BCL2 BCL6 BRAF EZH2
19	integument	MP:0010771	9.4	B2M BCL2 BCL6 BRAF EZH2 MAP2K1

Sources

Drugs & Therapeutics for Lymphoma, Non-Hodgkin, Familial

Drugs for Lymphoma, Non-Hodgkin, Familial (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 539)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Dacarbazine

Approved, Investigational

Phase 4

4342-03-4

2942 5351166

Morphine

Approved, Investigational

Phase 4

57-27-2

5288826

Miconazole

Approved, Investigational, Vet_approved

Phase 4

22916-47-8

4189

Clotrimazole

Approved, Vet_approved

Phase 4

23593-75-1

2812

Sirolimus

Approved, Investigational

Phase 4

53123-88-9

5284616 6436030

Plerixafor

Approved

Phase 4

110078-46-1

65015

Entecavir

Approved, Investigational

Phase 4

142217-69-4

153941

Nitrous oxide

Approved, Vet_approved

Phase 4

10024-97-2

948

Lidocaine

Approved, Vet_approved

Phase 4

137-58-6

3676

Nitric Oxide

Approved

Phase 4

10102-43-9

145068

Prilocaine

Approved

Phase 4

721-50-6

4906

Valsartan

Approved, Investigational

Phase 4

137862-53-4

60846

Pirarubicin

Investigational

Phase 4

72496-41-4

4844

Tenofovir

Experimental, Investigational

Phase 4

147127-20-6, 202138-50-9

464205 6398764

Dexchlorpheniramine

Experimental, Investigational

Phase 4

25523-97-1

33036

Antifungal Agents

Phase 4

Anti-Retroviral Agents

Phase 4

Anti-HIV Agents

Phase 4

Anti-Arrhythmia Agents

Phase 4

Angiotensin Receptor Antagonists

Phase 4

Angiotensin II Type 1 Receptor Blockers

Phase 4

Giapreza

Phase 4

Lidocaine, Prilocaine Drug Combination

Phase 4

Sodium Channel Blockers

Phase 4

Anesthetics, Inhalation

Phase 4

Anesthetics, General

Phase 4

Diuretics, Potassium Sparing

Phase 4

Heptavalent Pneumococcal Conjugate Vaccine

Phase 4

Epoetin Alfa

Phase 4

Hematinics

Phase 4

Chrysarobin

Phase 4

Aldesleukin

Approved

Phase 3

110942-02-4

Obinutuzumab

Approved, Investigational

Phase 3

949142-50-1

Allopurinol

Approved

Phase 3

315-30-0

2094 135401907

Dexrazoxane

Approved, Withdrawn

Phase 3

24584-09-6

71384

Histamine

Approved, Investigational

Phase 3

51-45-6

774

Acetaminophen

Approved

Phase 3

103-90-2

1983

Diphenhydramine

Approved, Investigational

Phase 3

147-24-0, 58-73-1

3100

Promethazine

Approved, Investigational

Phase 3

60-87-7

4927

Moxifloxacin

Approved, Investigational

Phase 3

186826-86-8, 354812-41-2, 151096-09-2

152946

Zoledronic acid

Approved

Phase 3

118072-93-8

68740

Bleomycin

Approved, Investigational

Phase 3

9041-93-4, 11056-06-7

5360373

Rasburicase

Approved, Investigational

Phase 3

134774-45-1

Calcium carbonate

Approved, Investigational

Phase 3

471-34-1

Oxaliplatin

Approved, Investigational

Phase 2, Phase 3

61825-94-3

43805 11947679 6857599

Cladribine

Approved, Investigational

Phase 3

4291-63-8

20279

Famotidine

Approved

Phase 3

76824-35-6

3325 5702160

Vinorelbine

Approved, Investigational

Phase 3

71486-22-1

44424639 60780

Enalaprilat

Approved

Phase 3

76420-72-9

6917719 5462501

Enalapril

Approved, Vet_approved

Phase 3

75847-73-3

40466924 5388962 5362032

Interventional clinical trials:

(show top 50) (show all 2064)

#	Name	Status	NCT ID	Phase	Drugs
1	PEG-rhG-CSF in Patients With Non-Hodgkin Lymphoma Receiving Chemotherapy to Prevent Neutropenia	Unknown status	NCT02996617	Phase 4	rhG-CSF regimen;Pegylated rhG-CSF regimen
2	Study of PD-1 Monoclonal Antibody in Combination With Chemotherapy in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma	Unknown status	NCT04134247	Phase 4	PD-1 combined with chemotherapy;chemotherapy
3	An Open-label,Multicenter Randomised Study of CTOP/ITE/MTX Compared With CHOP as the First-line Therapy for the New Diagnosed Young Patients With T Cell Non-hodgkin Lymphoma	Unknown status	NCT01746992	Phase 4	Cyclophosphamide 750mg/m2;Vincristine 1.4mg/m2;Doxorubicin 50mg/m2;prednisone 60mg/m2;ifosfamide 2000mg/m2;pirarubicin 50mg/m2;pirarubicin 25mg/m2;Etoposide phosphate 100mg/m2;methotrexate 1500mg/m2
4	Cost-Effectiveness Study of Pegylated Recombinant Human Granulocyte Colony-stimulating Factor(PEG-rhG-CSF) in Prophylactic Treatment of Neutropenia After Chemotherapy in Lymphoma	Unknown status	NCT04083079	Phase 4	PEG-rhG-CSF;rhG-CSF
5	Clinical Application of Polyethylene Glycol Liposome Doxorubicin (PLD) in Primary Lymphoma	Unknown status	NCT02526823	Phase 4	R-CHOP/CHOPE or ABVD chemotherapy regimen;R-CDOP/CDOPE or DBVD chemotherapy regimen
6	Intensification Therapy of Mature B-ALL, Burkitt and Burkitt Like and Other High Grade Non-Hodgkin's Lymphoma in Adults	Unknown status	NCT00797810	Phase 4	Rituximab
7	A Multicenter Study to Compare the Efficacy of a Prophylactic Use of Tenofovir by Duration for the Non-Hodgkin's Lymphoma Patients With Isolated Anti-HBc-positivity Who Will be Treated With Rituximab Based Chemotherapy	Unknown status	NCT02585947	Phase 4	Tenofovir
8	A Clinical Trial of Decitabine Combined With CODOX-M/IVAC in Relapsed or Refractory T-lymphoblastic Lymphoma	Unknown status	NCT03558412	Phase 4	Decitabine
9	Expanded Access Program of Pegfilgrastim in Patients With Non-Hodgkin Lymphoma (NHL)	Completed	NCT02782845	Phase 4	Chemotherapy;Immunochemotherapy;Pegfilgrastim
10	Prospective Non-randomized Multicenter Study to Assess the Efficacy Response Duration and Toxicity of RFC as First-line Treatment and R as Maintenance Treatment, in Patients Diagnosed of Follicular Non Hodgkin Lymphoma	Completed	NCT01124526	Phase 4	Rituximab Fludarabine Cyclophosphamide
11	Evaluation of the Analgesy Using a Local Anesthetic (Lidocaine and Prolocaine) Eutectic Mixture and/or Nitric Oxide at 50% in Oxygen (Livopan®) in Pediatric Patients That During Lumbar Puncture	Completed	NCT00808171	Phase 4	Livopan;EMLA
12	ALL-REZ BFM 2002: Protocol for the Treatment of Children With Relapsed Acute Lymphoblastic Leukemia	Completed	NCT00114348	Phase 4
13	Zevalin® (Ibritumomab Tiuxetan) Followed by Rituxan® (Rituximab) Maintenance in Previously Treated Low Grade Non-Hodgkin's Lymphoma	Completed	NCT00168727	Phase 4	ibritumomab tiuxetan (Zevalin®)
14	A Study to Evaluate the Safety of MabThera (Rituximab) Maintenance Therapy in Patients With Follicular Non-Hodgkin's Lymphoma Who Have Responded to Induction Therapy.	Completed	NCT00430352	Phase 4	rituximab [MabThera/Rituxan]
15	The Multi-centers Trial for Patients With Non-Hodgkin's Lymphoma to Assess the Protective Effect of Valsartan on Chronic Cardiotoxicity Induced by CHOP	Completed	NCT00162955	Phase 4	Valsartan
16	A Multicenter Study to Evaluate the Effect of Rituximab (IDEC-102) on Primary Humoral Response, Recall Response, and Maintenance of Acquired Immunity to Specific Antigens	Completed	NCT00090038	Phase 4	rituximab
17	Association Between Response to Aggressive Chemotherapy and Doxorubicin Pharmacokinetics in Non Hodgkin's Lymphoma Patients	Completed	NCT00969462	Phase 4	Doxorubicin
18	An Open-label, Single-arm Study of Palifermin for Reduction of Mucositis in Subjects With Non-Hodgkin's Lymphoma or Multiple Myeloma Undergoing High-Dose Chemotherapy and Autologous Peripheral Blood Stem Cell (PBSC) Transplantation	Completed	NCT00352703	Phase 4	Kepivance (Palifermin)
19	Prophylactic Use of Entecavir for Chemotherapy Associated With Hepatitis B Reactivation in HBsAg (-), Anti-HBc (+) Non-Hodgkin's Lymphoma Patients: a Randomized Controlled Trial	Completed	NCT00926757	Phase 4	Entecavir prophylaxis;Therapeutic entecavir
20	A Phase 4, Multicenter, Randomized, Comparator Trial Evaluating the Standard Weight-Based Dose (0.24 mg/kg) Compared to a Fixed Dose (20 mg) of Plerixafor Injection in Combination With G-CSF to Mobilize and Collect ≥5 x 10^6 CD34+ Cells/kg in ≤4 Days and to Evaluate the Difference in Total Systemic Exposure in Patients With Non-Hodgkin's Lymphoma Weighing ≤70 kg	Completed	NCT01164475	Phase 4	Granulocyte-colony stimulating factor (G-CSF);Fixed Dose Plerixafor;Weight-Based Plerixafor
21	A RANDOMIZED PHASE 4 STUDY COMPARING 2 INTRAVENOUS TEMSIROLIMUS (TEMSR) REGIMENS IN SUBJECTS WITH RELAPSED, REFRACTORY MANTLE CELL LYMPHOMA	Completed	NCT01180049	Phase 4	temsirolimus
22	B-cell Mature Non-Hodgkin's Lymphoma Treatment Protocol in Children and Adolescents 2021 (B-NHL-M-2021)	Recruiting	NCT05518383	Phase 4	Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate;Cyclophosphamide, Cytarabine, Dexamethasone, Etoposide, Ifosfamide, Methotrexate, Vincristine;Cyclophosphamide, Cytarabine, Dexamethasone, Doxorubicin hydrochloride, Etoposide, Ifosfamide, Methotrexate, vincristine;Cyclophosphamide , Cytarabine, Dexamethasone, Doxorubicin hydrochloride, Etoposide, Ifosfamide, Methotrexate, Vincristine, Сarboplatine, CCNU/ BCNU, Melphalan, Idarubicin
23	Immunogénicité de la Vaccination Anti-pneumococcique Dans la leucémie aiguë et le Lymphome Chez l'Adulte	Recruiting	NCT04460235	Phase 4	Prevenar13 Pneumo-23
24	Ultrafast Truxima Infusion in Non-Hodgkin's Lymphoma: Txagorapid Study - Intervention Pilot Study	Recruiting	NCT05191225	Phase 4	RiTUXimab Injection [Truxima]
25	A Phase 4, Open-label, Single-Arm Study of Brentuximab Vedotin in Patients With Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma	Active, not recruiting	NCT01909934	Phase 4	brentuximab vedotin
26	Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib After Completion of Ibrutinib Clinical Trials.	Enrolling by invitation	NCT03229200	Phase 4	Ibrutinib
27	Open Multicentric Study to Assess the Hematopoyetic Response in Terms of Increase of Hemoglobin Levels of Patients With Anemia Related to Non- Hodgkin Lymphoma, Chronic Lymphocytic Leukemia or Multiple Myeloma, Treated With Erythropoietin B (Recormon) Using Pre-filled Syringe With 30000 IU, as Well as to Quantify the Risk Factors of Anemia and Its Impact on Quality of Life Related to Treatment	Terminated	NCT02608060	Phase 4	Epoetin Beta
28	A Multicenter Prospective Study of Treatment ALK(+) Systemic Anaplastic Large Cell Lymphoma With Crizotinib	Withdrawn	NCT02487316	Phase 4	crizotinib
29	The Value of Dexamethasone Versus Prednisolone During Induction and Maintenance Therapy of Prolonged Versus Conventional Duration of L-Asparaginase Therapy During Consolidation and Late Intensification, and of Corticosteroid + VCR Pulses During Maintenance in Acute Lymphoblastic Leukemia and Lymphoblastic Non-Hodgkin Lymphoma of Childhood	Unknown status	NCT00003728	Phase 3	asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;doxorubicin hydrochloride;etoposide;leucovorin calcium;mercaptopurine;methotrexate;methylprednisolone;mitoxantrone hydrochloride;prednisolone;therapeutic hydrocortisone;thioguanine;vincristine sulfate;vindesine
30	Comparative,Randomized,Double Blind Study to Evaluate Biologic Effect and Safety of PBO-326 (Rituximab), Associated to CHOP-14 Compared With Mabthera (Rituximab) Associated to CHOP-14 in B Cells CD20+ Diffuse Non-Hodgkin Lymphoma Patients	Unknown status	NCT01277172	Phase 2, Phase 3
31	Intergroup Trial for Children or Adolescents With B-Cell Non Hodgkin Lymphoma or B-Acute Leukemia: Evaluation of Rituximab Efficacy and Safety in High Risk Patients - Phase III Trial	Unknown status	NCT01516580	Phase 3	Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C;Rituximab, Vincristine, cyclophosphamide, methotrexate, doxorubicin, cytarabine, ara-C
32	A Multicenter, Single Arm Clinical Trial in Patients With Rituximab Refractory B-cell Indolent Lymphoma	Unknown status	NCT01570049	Phase 3	Bendamustine
33	Treatment of Low-Grade Gastric Non-Hodgkin's Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT) Type Stages IE & II1E (HELYX-Study)	Unknown status	NCT00154440	Phase 3	proton pump inhibitor;clarithromycin;amoxicillin;metronidazole
34	Phase III Stidy of Zevalin And BEAM Compared With BEAM Alone Prior to Autologous Hematopoietic Steem Cell Transpl. in Pts Relapse of Non-Hodgkins Lymphoma	Unknown status	NCT00463463	Phase 3	90Yttrium Ibritumomab Tiuxetan (Zevalin)
35	A Multi-center, Prospective, Randomized Phase III Study of the Safety and Efficacy of R-CEOP-90/R-CEOP-70 Versus R-CHOP-50 in the Treatment of Diffuse Large B-cell Lymphoma and Follicular Lymphoma Grade 3B	Unknown status	NCT01852435	Phase 3	R-CEOP-70;R-CEOP-90;R-CHOP-50
36	Safety and Efficacy of Stem Cell Mobilization Using G-CSF (Filgrastim) Alone Compared to Intermediate-dose Cytosine Arabinoside Plus G-CSF in Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma Patients.	Unknown status	NCT02722733	Phase 3	G-CSF (filgrastim);Cytosine arabinoside with G-CSF (filgrastim)
37	A Randomized Phase III Study to Compare Conventional Chemotherapy (CHOEP-14) + Rituximab vs High-dose Chemotherapy Followed by Autologous Stem Cell Transplantation (Mega-CHOEP-21) + Rituximab in Younger Patients With Aggressive NHL	Unknown status	NCT00129090	Phase 3	R-CHOEP 14 with 12x Rituximab
38	A Phase III Clinical Trial of Immunotherapy With Humanized LL2 IgG (Epratuzumab) in Patients With Low-Grade Follicular, B-Cell Non-Hodgkin's Lymphoma Refractory to Rituxan (Rituximab)	Unknown status	NCT00022685	Phase 3
39	A Randomised Study of High Dose Chemotherapy/Radiotherapy and Autologous Bone Marrow Transplantation in Patients With High Grade Malignant Non-Hodgkin's Lymphoma (Kiel Classification) According to Prognostic Groups	Unknown status	NCT00003815	Phase 3	carmustine;cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide;melphalan;prednisolone;vincristine sulfate
40	A Randomized Phase III Study Of Chimeric Anti-CD20 Monoclonal Antibody (Rituximab) With 2-Weekly CHOP Chemotherapy In Elderly Patients With Intermediate Or High-Risk Non-Hodgkin's Lymphoma	Unknown status	NCT00028717	Phase 3	cyclophosphamide;doxorubicin hydrochloride;prednisone;vincristine sulfate
41	Randomized Trial of Patient-Specific Vaccination With Conjugated Follicular Lymphoma-Derived Idiotype (FNHLId1) With Local GM-CSF in First Complete Remission	Unknown status	NCT00091676	Phase 3
42	A Multi-Center, Randomized, Phase III Study of Rituximab Versus Iodine I 131 Tositumomab Therapy for Patients With Relapsed Follicular Non-Hodgkin's Lymphoma	Unknown status	NCT00078598	Phase 3	Rituximab or Iodine I 131 Tositumomab Therapy
43	A Phase III Trial To Evaluate The Safety And Efficacy Of Specific Immunotherapy, Recombinant Idiotype Conjugated To KLH With GM-CSF, Compared To Non-Specific Immunotherapy, KLH With GM-CSF, In Patients With Follicular Non-Hodgkin's Lymphoma	Unknown status	NCT00017290	Phase 3	cyclophosphamide;prednisone;vincristine sulfate
44	The Utility of LymphoScan Imaging in the Dectection of Residual Tumor After Chemotherapy and/or Radiotherapy in Patients With Non-Hodgkin's Lymphoma	Unknown status	NCT00003338	Phase 2, Phase 3
45	The Utility of LymphoScan Imaging in the Localization and Staging of Patients With Non-Hodgkin's Lymphoma	Unknown status	NCT00003337	Phase 3
46	Non-Hodgkin's Lymphoma T Cell Protocol	Unknown status	NCT00003423	Phase 3	asparaginase;cyclophosphamide;cytarabine;daunorubicin hydrochloride;dexamethasone;etoposide;mercaptopurine;methotrexate;prednisolone;thioguanine;vincristine sulfate
47	Randomised Controlled Trial of CID (Chlorambucil, Idarubicin, Dexamethasone) Versus CD (Chlorambucil, Dexamethasone) for Induction of Remission in Low Grade Non-Hodgkin's Lymphoma (Kiel Classification) Followed by Randomised Controlled Assessment of Standard Dose Interferon Versus Low Dose Interferon Versus No Further Therapy as Maintenance Treatment After Remission Induction	Unknown status	NCT00003639	Phase 3	chlorambucil;dexamethasone;idarubicin
48	An Open-Label, One-Arm, Multi-Site Trial of Precision Diagnosis Directing Histone Deacetylase Inhibitor Chidamide Total Therapy for Adult T-lymphoblastic Lymphoma/Leukemia	Unknown status	NCT03564704	Phase 2, Phase 3	Dexamethasone;vincristine;Cyclophosphamide;Idarubicin;Pegaspargase;Adriamycin;Methotrexate;6-mercaptopurine.;Etoposide;Cytarabine;Chidamide
49	A European Randomized Multicenter Study of Interferon Alfa-2b Versus No Treatment After Intensive Therapy and Autologous Hematopoietic Stem Cell Transplantation for Relapsing Lymphoma Patients (Non-Hodgkin Lymphomas and Hodgkin's Disease)	Unknown status	NCT00003924	Phase 3
50	A Multi-center Phase III Study Comparing Nonmyeloablative Conditioning With TBI Versus Fludarabine/TBI for HLA-matched Related Hematopoietic Cell Transplantation for Treatment of Hematologic Malignancies	Completed	NCT00075478	Phase 3	Fludarabine Phosphate;Mycophenolate Mofetil;Cyclosporine

Search NIH Clinical Center for Lymphoma, Non-Hodgkin, Familial

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

Aldesleukin

bendamustine

Carmustine

Chlorambucil

Cisplatin

CISPLATIN PWDR

Cladribine

fludarabine

Fludarabine phosphate

Ifosfamide

Lomustine

mercaptopurine

pegaspargase

Procarbazine

Procarbazine Hydrochloride

sargramostim

Vincristine

Vincristine Sulfate

Cell-based therapeutics:

Data from LifeMap, the Embryonic Development and Stem Cells Database

Read about Lymphoma, Non-Hodgkin, Familial cell therapies at LifeMap Discovery.

Stem-cell-based therapeutic approaches for Lymphoma, Non-Hodgkin, Familial:

	Blood stem cell transplantation for hematological diseases
	Hematopoietic stem cells for treatment of hematologic malignancies
	Hematopoietic stem cells for treatment of non-Hodgkin's lymphoma
	StemEx, umbilical cord blood stem/progenitor cells for hematological diseases

Embryonic/Adult Cultured Cells Related to Lymphoma, Non-Hodgkin, Familial:

	Peripheral blood-derived hematopoietic stem cells (family)
	Bone marrow-derived hematopoietic stem cells
	Peripheral blood-derived hematopoietic stem cells PMIDs: 21831743
	Umbilical cord blood stem/progenitor cells (Stemex) PMIDs: 18209724

Cochrane evidence based reviews: lymphoma, non-hodgkin

Sources

Genetic Tests for Lymphoma, Non-Hodgkin, Familial

Genetic tests related to Lymphoma, Non-Hodgkin, Familial:

#	Genetic test	Affiliating Genes
1	Non-Hodgkin Lymphoma ²⁸
2	Lymphoma, Non-Hodgkin, Familial ²⁸	BCL10 CASP10 PRF1 RAD54B RAD54L

Sources

Anatomical Context for Lymphoma, Non-Hodgkin, Familial

Organs/tissues related to Lymphoma, Non-Hodgkin, Familial:

MalaCards : T Cells, Bone Marrow, Bone, B Cells, Nk Cells, Breast, Lymph Node

Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Lymphoma, Non-Hodgkin, Familial:

#	Tissue Anatomical CompartmentCell	Relevance
1	Blood Hematopoietic Bone Marrow Hematopoietic Stem Cells	Potential therapeutic candidate
2	Blood Peripheral Blood Mature B-Cells	Affected by disease

Sources

Publications for Lymphoma, Non-Hodgkin, Familial

Articles related to Lymphoma, Non-Hodgkin, Familial:

(show top 50) (show all 17731)

#	Title	Authors	PMID	Year
1	Inactivating mutations of CASP10 gene in non-Hodgkin lymphomas. ⁵³ ⁶² ⁵	Shin MS...Lee SH	12010812	2002
2	Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma. ⁶² ⁵⁷	Morin RD...Marra MA	21796119	2011
3	Familial risk for non-Hodgkin lymphoma and other lymphoproliferative malignancies by histopathologic subtype: the Swedish Family-Cancer Database. ⁶² ⁵⁷	Altieri A...Hemminki K	15811955	2005
4	A proportion of patients with lymphoma may harbor mutations of the perforin gene. ⁶² ⁵⁷	Clementi R...Roncarolo MG	15728124	2005
5	Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity. ⁵	Chang MT...Taylor BS	26619011	2016
6	A tumour suppressor network relying on the polyamine-hypusine axis. ⁵⁷	Scuoppo C...Lowe SW	22722845	2012
7	Inactivating mutations of acetyltransferase genes in B-cell lymphoma. ⁵⁷	Pasqualucci L...Dalla-Favera R	21390126	2011
8	Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin. ⁵⁷	Morin RD...Marra MA	20081860	2010
9	Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma. ⁵⁷	Davis RE...Staudt LM	20054396	2010
10	Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma. ⁵⁷	Compagno M...Pasqualucci L	19412164	2009
11	Oncogenic CARD11 mutations in human diffuse large B cell lymphoma. ⁵⁷	Lenz G...Staudt LM	18323416	2008
12	BRAF mutations in non-Hodgkin's lymphoma. ⁵	Lee JW...Lee SH	14612909	2003
13	BRAF mutations in metastatic melanoma: a possible association with clinical outcome. ⁵	Kumar R...Hemminki K	12960123	2003
14	Inactivating mutations of the caspase-10 gene in gastric cancer. ⁵	Park WS...Lee JY	11973654	2002
15	Age of onset evidence for anticipation in familial non-Hodgkin's lymphoma. ⁵⁷	Wiernik PH...Paietta E	10651726	2000
16	Mutations of a novel human RAD54 homologue, RAD54B, in primary cancer. ⁵	Hiramoto T...Kamiya K	10362364	1999
17	Mutations in the RAD54 recombination gene in primary cancers. ⁵	Matsuda M...Kamiya K	10362365	1999
18	Bcl10 is involved in t(1;14)(p22;q32) of MALT B cell lymphoma and mutated in multiple tumor types. ⁵	Willis TG...Dyer MJ	9989495	1999
19	Germline mutations of the p53 tumor-suppressor gene in children and young adults with second malignant neoplasms. ⁵	Malkin D...Garber J	1565144	1992
20	Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia. ⁵³ ⁶²	Friedberg JW...Shipp MA	19965662	2010
21	Mantle cell lymphoma: report of the 2009 Mantle Cell Lymphoma Consortium Workshop. ⁵³ ⁶²	Williams ME...Wilson WH	20038219	2010
22	An intronic polymorphism of IRF4 gene influences gene transcription in vitro and shows a risk association with childhood acute lymphoblastic leukemia in males. ⁵³ ⁶²	Do TN...Dorak MT	19897031	2010
23	Genetic variation in N-acetyltransferases 1 and 2, cigarette smoking, and risk of non-Hodgkin lymphoma. ⁵³ ⁶²	Kilfoy BA...Zhang Y	19809881	2010
24	Interaction between organochlorines and the AHR gene, and risk of non-Hodgkin lymphoma. ⁵³ ⁶²	Ng CH...Spinelli JJ	19821039	2010
25	Interleukin-15 affects patient survival through natural killer cell recovery after autologous hematopoietic stem cell transplantation for non-Hodgkin lymphomas. ⁵³ ⁶²	Porrata LF...Markovic SN	20414345	2010
26	A pharmacokinetic study of plerixafor in subjects with varying degrees of renal impairment. ⁵³ ⁶²	MacFarland R...Calandra G	19748593	2010
27	Identification, characterisation and regulation by CD40 activation of novel CD95 splice variants in CD95-apoptosis-resistant, human, B-cell non-Hodgkin's lymphoma. ⁵³ ⁶²	Lajmanovich A...Callanan MB	19751723	2009
28	Genetic variation in the NBS1, MRE11, RAD50 and BLM genes and susceptibility to non-Hodgkin lymphoma. ⁵³ ⁶²	Schuetz JM...Brooks-Wilson AR	19917125	2009
29	Speckled-like pattern in the germinal center (SLIP-GC), a nuclear GTPase expressed in activation-induced deaminase-expressing lymphomas and germinal center B cells. ⁵³ ⁶²	Richter K...Diaz M	19734146	2009
30	Relationship between interferon regulatory factor 4 genetic polymorphisms, measures of sun sensitivity and risk for non-Hodgkin lymphoma. ⁵³ ⁶²	Gathany AH...Wang SS	19396635	2009
31	Haploidentical hematopoietic stem-cell transplantation for non-Hodgkin lymphoma with bone marrow involvement. ⁵³ ⁶²	Wang HX...Guo ZK	19811326	2009
32	[Genetic susceptibility of single nucleotide polymorphism in MGMT to non-Hodgkin lymphoma]. ⁵³ ⁶²	Yang F...Shen ZX	19954624	2009
33	Allelic genotyping reveals a hierarchy of genomic alterations in mantle cell lymphoma associated to cell proliferation. ⁵³ ⁶²	Hutter G...Dreyling M	19137297	2009
34	Plerixafor hydrochloride: a novel agent for the mobilization of peripheral blood stem cells. ⁵³ ⁶²	Cashen AF	19834627	2009
35	CMC-544 (inotuzumab ozogamicin) shows less effect on multidrug resistant cells: analyses in cell lines and cells from patients with B-cell chronic lymphocytic leukaemia and lymphoma. ⁵³ ⁶²	Takeshita A...Ohno R	19388933	2009
36	Absence of tumor-specific over-expression of Polo-like kinase 1 (Plk1) in major non-Hodgkin lymphoma and relatively low expression of Plk1 in nasal NK/T cell lymphoma. ⁵³ ⁶²	Imai H...Oshimi K	19452252	2009
37	Genetic variation in B-cell-activating factor is associated with an increased risk of developing B-cell non-Hodgkin lymphoma. ⁵³ ⁶²	Novak AJ...Ansell SM	19383901	2009
38	BAFF-R promotes cell proliferation and survival through interaction with IKKbeta and NF-kappaB/c-Rel in the nucleus of normal and neoplastic B-lymphoid cells. ⁵³ ⁶²	Fu L...Ford RJ	19258594	2009
39	FBXW7 and NOTCH1 mutations in childhood T cell acute lymphoblastic leukaemia and T cell non-Hodgkin lymphoma. ⁵³ ⁶²	Park MJ...Hayashi Y	19245433	2009
40	Stabilization and activation of p53 downregulates mTOR signaling through AMPK in mantle cell lymphoma. ⁵³ ⁶²	Drakos E...Rassidakis GZ	19225536	2009
41	Pax5 immunostaining in paraffin-embedded sections of canine non-Hodgkin lymphoma: a novel canine pan pre-B- and B-cell marker. ⁵³ ⁶²	Willmann M...Thalhammer JG	19100628	2009
42	Mouse models of non-Hodgkin lymphoma reveal Syk as an important therapeutic target. ⁵³ ⁶²	Young RM...Refaeli Y	18981293	2009
43	Targeting CD40 in Waldenström's macroglobulinemia. ⁵³ ⁶²	Lee M...Advani R	19362983	2009
44	Pharmacokinetics and pharmacodynamics of plerixafor in patients with non-Hodgkin lymphoma and multiple myeloma. ⁵³ ⁶²	Stewart DA...Calandra G	19135941	2009
45	Expression of activation-induced cytidine deaminase in malignant lymphomas infiltrating the bone marrow. ⁵³ ⁶²	Engels K...Willenbrock K	18776814	2008
46	A phase II study of plerixafor (AMD3100) plus G-CSF for autologous hematopoietic progenitor cell mobilization in patients with Hodgkin lymphoma. ⁵³ ⁶²	Cashen A...DiPersio J	18940680	2008
47	Expression of cannabinoid receptors type 1 and type 2 in non-Hodgkin lymphoma: growth inhibition by receptor activation. ⁵³ ⁶²	Gustafsson K...Sander B	18546271	2008
48	Primary tracheal lymphoma causing respiratory failure. ⁵³ ⁶²	Tan DS...Tao M	18670314	2008
49	Serum CA125 and PSA concentrations in patients with lymphoma. ⁵³ ⁶²	Wiernik PH	18654120	2008
50	Polymorphisms of human N-acetyltransferases and cancer risk. ⁵³ ⁶²	Agundez JA	18680472	2008

Sources

Genes for Lymphoma, Non-Hodgkin, Familial

Genes related to Lymphoma, Non-Hodgkin, Familial (8 elite genes):

(show top 50) (show all 256)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence	PubMed IDs
1	CASP10	Caspase 10	Protein Coding	1308	Molecular basis known ⁵⁷ Pathogenic ⁵ Causative variation ⁷³ Genetic Tests ²⁸ DISEASES inferred ¹⁴ Novoseek inferred ⁵³	11973654 12010812 20025484
2	BCL10	BCL10 Immune Signaling Adaptor	Protein Coding	1063.4	Molecular basis known ⁵⁷ Pathogenic ⁵ Genetic Tests ²⁸ Susceptibility factor ⁵⁷ DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9989495 11425462 10665648 (more) 18346354 11372735 10803524 11748643
3	RAD54L	RAD54 Like	Protein Coding	1003.71	Molecular basis known ⁵⁷ Pathogenic ⁵ Genetic Tests ²⁸ DISEASES inferred ¹⁴	10362365
4	RAD54B	RAD54 Homolog B	Protein Coding	1003.32	Molecular basis known ⁵⁷ Pathogenic ⁵ Genetic Tests ²⁸ DISEASES inferred ¹⁴	10362364
5	BRAF	B-Raf Proto-Oncogene, Serine/Threonine Kinase	Protein Coding	705.37	Pathogenic ⁵ Causative variation ⁷³ DISEASES inferred ¹⁴	12960123 14612909
6	PRF1	Perforin 1	Protein Coding	607.31	Molecular basis known ⁵⁷ Genetic Tests ²⁸ DISEASES inferred ¹⁴
7	B2M	Beta-2-Microglobulin	Protein Coding	438.85	Pathogenic ⁵ Likely pathogenic ⁵ DISEASES inferred ¹⁴ Novoseek inferred ⁵³	26619011 10342582 8496627 (more) 16545870 1414221 9329587
8	TP53	Tumor Protein P53	Protein Coding	433.85	Pathogenic ⁵ Likely pathogenic ⁵ DISEASES inferred ¹⁴	1565144 26619011
9	FAS-AS1	FAS Antisense RNA 1	RNA Gene	155.04	Experimental evidence ³⁷ DISEASES inferred ¹⁴	24811343
10	MYC	MYC Proto-Oncogene, BHLH Transcription Factor	Protein Coding	40.95	Likely pathogenic ⁵ DISEASES inferred ¹⁴ Novoseek inferred ⁵³	26619011 11343379 8574164 (more) 10602433 10323217 9563496 18754028 9088026 8580815 12745652 1493439 1485535 8043869 19670467 12594230 9364867 1457505 2200538 1764535 19844983 9573674 1342969 1769408 1387833 8615659 17701581 1352077 18981293
11	EZH2	Enhancer Of Zeste 2 Polycomb Repressive Complex 2 Subunit	Protein Coding	32.9	Likely pathogenic ⁵ DISEASES inferred ¹⁴	26619011
12	MYD88	MYD88 Innate Immune Signal Transduction Adaptor	Protein Coding	32.87	Likely pathogenic ⁵ DISEASES inferred ¹⁴	26619011
13	RHOA	Ras Homolog Family Member A	Protein Coding	31.74	Likely pathogenic ⁵ DISEASES inferred ¹⁴	26619011
14	PIK3CA	Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Alpha	Protein Coding	31.64	Likely pathogenic ⁵ DISEASES inferred ¹⁴	26619011
15	MAP2K1	Mitogen-Activated Protein Kinase Kinase 1	Protein Coding	31.41	Likely pathogenic ⁵ DISEASES inferred ¹⁴	26619011
16	NRAS	NRAS Proto-Oncogene, GTPase	Protein Coding	31.36	Likely pathogenic ⁵ DISEASES inferred ¹⁴	26619011
17	IRF4	Interferon Regulatory Factor 4	Protein Coding	20.32	DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³	19396635 19897031 12594241
18	BCL6	BCL6 Transcription Repressor	Protein Coding	19.84	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	7742550 10953971 16125304 (more) 7472775 17142954 11742039 8618443 15024721 7794763 16249378 10233393 8758205 16867873 15256116 12414651 8988030 8025268 8652841 9184180 8703825 8063612 16815642 16331266 11579468 11516111 10490843 9824206 9642131 9209377 9160681 7669745 15611930 12835729 9796700 17404575 14513282 12594230 12555064 12173331 10666217 9402330 11914273 11780315 11157493 11920179 9824205 9747876 9573674 7639334 8142643 15202519 11865059 10898795 10637510 7795234 16264183 16772123 11290603 9504630 9359519 9921651
19	BCL2	BCL2 Apoptosis Regulator	Protein Coding	18.98	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	15503680 11380403 9113013 (more) 1747446 8220159 15061204 15669024 8574164 7632955 9088026 8436340 9207459 8558921 8547651 7581933 7819053 8417786 19537891 9758366 9587934 11855781 9002964 11866986 2223650 10794603 1290353 8080035 7949096 8667654 8945612 8774139 1602814 1757070 16840203 15550595 11722998 9665466 9349233 8104532 18287262 17916949 17404107 11113864 9655306 9443038 9413633 11877091 16156855 15794866 15784299 11679800 10074891 8704213 8535193 7981893 7950302 8297731 15611930 10564590 9591044 7695015 8400801 8418370 1581893 9573674 8732086 7790118 7937722 8220113 1774956 2249898 17074584 16193090 9343323 7981903 7519826 8172820 1342969 1485535 1391959 9276187 15846077 15255171 15077178 10766396 8204892 1387833 1339299 1742726 18929412 12210808 9712423 9681218 7505024 1633729 16518606 15377339 7723399 11818669
20	TNFRSF8	TNF Receptor Superfamily Member 8	Protein Coding	18.71	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	8055109 7982672 7564510 (more) 10793083 1849500 1850308 1329671 8204884 7591296 14692525 15189504 19760074 8833395 2173674 9206929 10628334 7875968 11862770 1330287 8781434 16533741 7745117
21	ALK	ALK Receptor Tyrosine Kinase	Protein Coding	17.81	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9174053 15938644 9121481 (more) 17694547 18670314 8122112 7824924 14569815 14506160 9763551 15852431 18974134
22	CSF3	Colony Stimulating Factor 3	Protein Coding	17.3	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	19233728 8908287 11920216 (more) 12629058 15654353 17177909 9006749 10975387 7540461 7692189 11091498 18594529 14979480 9213175 9181898 8598236 7507533 7684011 14556680 8691577 7541257 7563935 7543059 1381626 16646673 12196361 9053502 19167685 18567557 17994119 18794865 17582943 11007055 10761530 9605644 9562926 19816079 10731947 16930137 1702132 1375485 7686283 8759907 9638986 10706456 16585020 8864456 8928121 8733686 7540401 7535843 7530468 7517260 19834627 16863911 19811326 11896424 11813173 11091491 11019842 11019835 10561192 9829733 9037362 11106111 10793559 10350339 9737696 9658727 9166835 7516922 1699654 17324009 19135941 12406901 12436219 11797111 11732872 16525786 16533747 12886256 12478902 11466671 11239168 11342310 10813543 10197794 10791904 9369412 8649061 7539658 7524599 19597422 19483760 8982296 7543069 7539966 18669165 15550484
23	PAX5	Paired Box 5	Protein Coding	16.61	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	16648862 19100628 9694719 (more) 17016584 17717600 9722295 12360049 16968900 17717432 9850179 10556196 10071452 14676435
24	CCND1	Cyclin D1	Protein Coding	16.59	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	10622539 7534138 9001420 (more) 9846986 9028966 10941340 7540362 16001955 16321849 1757070 7670110 7531681 9573674 8172823 1485535 19137297 19225536 16783567 16023083 12411587 7545645 12474231 9548443 7579380 7981893 16624404 9551917 9376597 12011261 20038219 12846895 12683869 16925576 7753558 17722077 16093790 11863220 9200999 1290353
25	MS4A1	Membrane Spanning 4-Domains A1	Protein Coding	16.06	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	15944291 11924912 16367924 (more) 12411587 1449258 12894078 14632776 19276251
26	CD5	CD5 Molecule	Protein Coding	15.82	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	1370753 9615189 8744680
27	PTPRC	Protein Tyrosine Phosphatase Receptor Type C	Protein Coding	15.5	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	1829834 1845482 1669003
28	NPM1	Nucleophosmin 1	Protein Coding	14.77	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9121481 8122112 7824924 (more) 9174053
29	IL2	Interleukin 2	Protein Coding	14.48	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	15148492 2043594 7530170 (more) 12478000 15073100 1504052 1727923 18256325 15595640 2305833 7493395 2249592 8334424 10585595 8374518 11565839 1405755 1634929 15447996 11477458 7654854 1868045 2036661 8523344 17889355 17145827 14695220 8831999 20193734 16690518 17198084 12580972 10706460 7693434 17697543 1568183 1827736 17026825 9457395 8907277 1635170 14502258 8181576 8968107 1391948 12623838 7578523 1831682 7773948 10689713
30	CD19	CD19 Molecule	Protein Coding	14.47	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	1706642 7517719
31	MALT1	MALT1 Paracaspase	Protein Coding	14.12	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	12560219 15598810
32	CCR6	C-C Motif Chemokine Receptor 6	Protein Coding	13.92	DISEASES inferred ¹⁴ ¹⁴ Novoseek inferred ⁵³	12514792
33	CSF2	Colony Stimulating Factor 2	Protein Coding	13.53	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	15989703 1859894 7980802 (more) 8616084 9171066 7511017 10561192 16041313 1679155 8648384 7950158 14682115 2185337 9193361
34	MIR199A1	MicroRNA 199a-1	RNA Gene	13.52	DISEASES inferred ¹⁴ ¹⁴ ¹⁴
35	IL3	Interleukin 3	Protein Coding	13.13	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	8523344 9592981 18214283 (more) 8218491 14770420 9225366 7698300 8542941 8639889 8440338 8547077 9543065 10561192
36	IL2RA	Interleukin 2 Receptor Subunit Alpha	Protein Coding	12.94	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9732831 7933620 8496627 (more) 9166099 1727208 9437500 15899555 7679589 8494993 1394062 8082082 2068535 7819101 8678534 9329587 12443879 2206570 8067207 7553687 11924909 16690518 7719243 1414221 11168504 8019399 8260527 18030581 9206929
37	MCL1	MCL1 Apoptosis Regulator, BCL2 Family Member	Protein Coding	12.87	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9591044 15343511 8080035 (more) 11818669 8686741 17430669
38	CD52	CD52 Molecule	Protein Coding	12.86	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	11807632 9126378 8027367
39	CD40	CD40 Molecule	Protein Coding	12.86	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	7507299 9767448 19751723 (more) 7530508 1702326 9056740 8541553 8819071 9163608 16166310 17456057 19362983
40	GZMB	Granzyme B	Protein Coding	12.75	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	11594520
41	BCL2L1	BCL2 Like 1	Protein Coding	12.73	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	11835337 17096886 16081784 (more) 8686741 14617792 8616083
42	CD44	CD44 Molecule (Indian Blood Group)	Protein Coding	12.52	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	10342571 7525912 10425314 (more) 8459220 11263339 7537983 10979212 7511297 7513537 7630011 11472578 9067581 9111868 7504454 16116502 12484499 11863224 10349995 7545748 7553660 8960109 9231152 10023342 2201831
43	MIR17	MicroRNA 17	RNA Gene	12.36	DISEASES inferred ¹⁴ ¹⁴
44	CD38	CD38 Molecule	Protein Coding	12.35	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	9206929 1449258
45	TNFSF13B	TNF Superfamily Member 13b	Protein Coding	12.31	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	17026820 19291294 19383901 (more) 16497967 14978135
46	CD27	CD27 Molecule	Protein Coding	12.22	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	12685844 12743427 17456057
47	MIR155	MicroRNA 155	RNA Gene	12.17	DISEASES inferred ¹⁴ ¹⁴
48	FCGR3A	Fc Gamma Receptor IIIa	Protein Coding	12.16	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	17650444
49	H2AC18	H2A Clustered Histone 18	Protein Coding	12.15	DISEASES inferred ¹⁴ ¹⁴
50	CCND3	Cyclin D3	Protein Coding	12.13	DISEASES inferred ¹⁴ Novoseek inferred ⁵³	11242797 16620575 12383214 (more) 11895902 12898595 12594230 9713342 15305377

Sources

Variations for Lymphoma, Non-Hodgkin, Familial

ClinVar genetic disease variations for Lymphoma, Non-Hodgkin, Familial:

⁵ (show top 50) (show all 67)

#	Gene	Name	Type	Significance	ClinVarId	dbSNP ID	Position
1	RAD54L	NM_003579.4(RAD54L):c.1331T>A (p.Val444Glu)	SNV	Pathogenic	6192	rs121908689	GRCh37: 1:46738430-46738430 GRCh38: 1:46272758-46272758
2	BCL10	NM_003921.5(BCL10):c.427_428dup (p.Glu145fs)	DUP	Pathogenic	6253	rs587776632	GRCh37: 1:85733583-85733584 GRCh38: 1:85267900-85267901
3	BCL10	NM_003921.5(BCL10):c.231dup (p.Gly78fs)	DUP	Pathogenic	6254	rs587776633	GRCh37: 1:85736415-85736416 GRCh38: 1:85270732-85270733
4	BCL10	NM_003921.5(BCL10):c.525_541del (p.Val176fs)	DEL	Pathogenic	6255	rs587776634	GRCh37: 1:85733471-85733487 GRCh38: 1:85267788-85267804
5	BCL10	NM_003921.5(BCL10):c.410del (p.Asn137fs)	DEL	Pathogenic	6256	rs587776635	GRCh37: 1:85733602-85733602 GRCh38: 1:85267919-85267919
6	BCL10	NM_003921.5(BCL10):c.398dup (p.Ser134fs)	DUP	Pathogenic	6257	rs587776636	GRCh37: 1:85733613-85733614 GRCh38: 1:85267930-85267931
7	BCL10	NM_003921.5(BCL10):c.629AAG[2] (p.Glu212del)	MICROSAT	Pathogenic	6258	rs587776637	GRCh37: 1:85733375-85733377 GRCh38: 1:85267692-85267694
8	CASP10	NM_032977.4(CASP10):c.1241C>T (p.Ala414Val)	SNV	Pathogenic	7765	rs28936699	GRCh37: 2:202074111-202074111 GRCh38: 2:201209388-201209388
9	CASP10	NM_032977.4(CASP10):c.769C>T (p.Gln257Ter)	SNV	Pathogenic	7766	rs121909775	GRCh37: 2:202070652-202070652 GRCh38: 2:201205929-201205929
10	CASP10	NM_032977.4(CASP10):c.1042_1043insA (p.Gly348fs)	INSERT	Pathogenic	7767	rs398122800	GRCh37: 2:202073912-202073913 GRCh38: 2:201209189-201209190
11	BRAF	NM_004333.6(BRAF):c.1405G>C (p.Gly469Arg)	SNV	Pathogenic	13970	rs121913357	GRCh37: 7:140481403-140481403 GRCh38: 7:140781603-140781603
12	BRAF	NM_004333.6(BRAF):c.1406G>C (p.Gly469Ala)	SNV	Pathogenic	13971	rs121913355	GRCh37: 7:140481402-140481402 GRCh38: 7:140781602-140781602
13	BRAF	NM_004333.6(BRAF):c.1781A>G (p.Asp594Gly)	SNV	Pathogenic	13972	rs121913338	GRCh37: 7:140453154-140453154 GRCh38: 7:140753354-140753354
14	RAD54B	NM_012415.3(RAD54B):c.1778A>G (p.Asn593Ser)	SNV	Pathogenic	5638	rs114216685	GRCh37: 8:95403868-95403868 GRCh38: 8:94391640-94391640
15	B2M	NM_004048.4(B2M):c.286G>A (p.Asp96Asn)	SNV	Pathogenic	31907	rs398122820	GRCh37: 15:45007839-45007839 GRCh38: 15:44715641-44715641
16	TP53	NM_000546.6(TP53):c.974G>T (p.Gly325Val)	SNV	Pathogenic	12367	rs121912659	GRCh37: 17:7576872-7576872 GRCh38: 17:7673554-7673554
17	TP53	NM_000546.6(TP53):c.844C>T (p.Arg282Trp)	SNV	Likely Pathogenic	12364	rs28934574	GRCh37: 17:7577094-7577094 GRCh38: 17:7673776-7673776
18	TP53	NM_000546.6(TP53):c.845G>C (p.Arg282Pro)	SNV	Likely Pathogenic	376659	rs730882008	GRCh37: 17:7577093-7577093 GRCh38: 17:7673775-7673775
19	TP53	NM_000546.6(TP53):c.722C>T (p.Ser241Phe)	SNV	Likely Pathogenic	12359	rs28934573	GRCh37: 17:7577559-7577559 GRCh38: 17:7674241-7674241
20	TP53	NM_000546.6(TP53):c.844C>G (p.Arg282Gly)	SNV	Likely Pathogenic	140821	rs28934574	GRCh37: 17:7577094-7577094 GRCh38: 17:7673776-7673776
21	TP53	NM_000546.6(TP53):c.721T>G (p.Ser241Ala)	SNV	Likely Pathogenic	376665	rs1057520002	GRCh37: 17:7577560-7577560 GRCh38: 17:7674242-7674242
22	TP53	NM_000546.6(TP53):c.614A>G (p.Tyr205Cys)	SNV	Likely Pathogenic	376681	rs1057520007	GRCh37: 17:7578235-7578235 GRCh38: 17:7674917-7674917
23	TP53	NM_000546.6(TP53):c.613T>C (p.Tyr205His)	SNV	Likely Pathogenic	376685	rs1057520008	GRCh37: 17:7578236-7578236 GRCh38: 17:7674918-7674918
24	TP53	NM_000546.6(TP53):c.845G>A (p.Arg282Gln)	SNV	Likely Pathogenic	237956	rs730882008	GRCh37: 17:7577093-7577093 GRCh38: 17:7673775-7673775
25	TP53	NM_000546.6(TP53):c.613T>A (p.Tyr205Asn)	SNV	Likely Pathogenic	376684	rs1057520008	GRCh37: 17:7578236-7578236 GRCh38: 17:7674918-7674918
26	TP53	NM_000546.6(TP53):c.722C>G (p.Ser241Cys)	SNV	Likely Pathogenic	177791	rs28934573	GRCh37: 17:7577559-7577559 GRCh38: 17:7674241-7674241
27	TP53	NM_000546.6(TP53):c.721T>C (p.Ser241Pro)	SNV	Likely Pathogenic	376664	rs1057520002	GRCh37: 17:7577560-7577560 GRCh38: 17:7674242-7674242
28	TP53	NM_000546.6(TP53):c.614A>T (p.Tyr205Phe)	SNV	Likely Pathogenic	376682	rs1057520007	GRCh37: 17:7578235-7578235 GRCh38: 17:7674917-7674917
29	TP53	NM_000546.6(TP53):c.613T>G (p.Tyr205Asp)	SNV	Likely Pathogenic	376686	rs1057520008	GRCh37: 17:7578236-7578236 GRCh38: 17:7674918-7674918
30	TP53	NM_000546.6(TP53):c.722C>A (p.Ser241Tyr)	SNV	Likely Pathogenic	376663	rs28934573	GRCh37: 17:7577559-7577559 GRCh38: 17:7674241-7674241
31	TP53	NM_000546.6(TP53):c.614A>C (p.Tyr205Ser)	SNV	Likely Pathogenic	376683	rs1057520007	GRCh37: 17:7578235-7578235 GRCh38: 17:7674917-7674917
32	MYD88	NM_002468.5(MYD88):c.755T>C (p.Leu252Pro)	SNV	Likely Pathogenic	37055	rs387907272	GRCh37: 3:38182641-38182641 GRCh38: 3:38141150-38141150
33	PIK3CA	NM_006218.4(PIK3CA):c.1031T>G (p.Val344Gly)	SNV	Likely Pathogenic	376497	rs1057519941	GRCh37: 3:178921549-178921549 GRCh38: 3:179203761-179203761
34	MYC	NM_002467.6(MYC):c.173C>T (p.Pro58Leu)	SNV	Likely Pathogenic	376459	rs1057519918	GRCh37: 8:128750636-128750636 GRCh38: 8:127738390-127738390
35	RHOA	NM_001664.4(RHOA):c.125A>C (p.Tyr42Ser)	SNV	Likely Pathogenic	376523	rs1057519954	GRCh37: 3:49412898-49412898 GRCh38: 3:49375465-49375465
36	MYC	NM_002467.6(MYC):c.218C>T (p.Thr73Ile)	SNV	Likely Pathogenic	376300	rs756091827	GRCh37: 8:128750681-128750681 GRCh38: 8:127738435-127738435
37	MAP2K1	NM_002755.4(MAP2K1):c.171G>C (p.Lys57Asn)	SNV	Likely Pathogenic	376174	rs869025608	GRCh37: 15:66727455-66727455 GRCh38: 15:66435117-66435117
38	B2M	NM_004048.4(B2M):c.2T>G (p.Met1Arg)	SNV	Likely Pathogenic	376372	rs1057519879	GRCh37: 15:45003746-45003746 GRCh38: 15:44711548-44711548
39	RHOA	NM_001664.4(RHOA):c.13C>T (p.Arg5Trp)	SNV	Likely Pathogenic	376519	rs1057519952	GRCh37: 3:49413010-49413010 GRCh38: 3:49375577-49375577
40	RHOA	NM_001664.4(RHOA):c.14G>T (p.Arg5Leu)	SNV	Likely Pathogenic	376521	rs1057519953	GRCh37: 3:49413009-49413009 GRCh38: 3:49375576-49375576
41	B2M	NM_004048.4(B2M):c.3G>A (p.Met1Ile)	SNV	Likely Pathogenic	376368	rs1057519877	GRCh37: 15:45003747-45003747 GRCh38: 15:44711549-44711549
42	MYC	NM_002467.6(MYC):c.217A>C (p.Thr73Pro)	SNV	Likely Pathogenic	376458	rs750664148	GRCh37: 8:128750680-128750680 GRCh38: 8:127738434-127738434
43	B2M	NM_004048.4(B2M):c.2T>C (p.Met1Thr)	SNV	Likely Pathogenic	376371	rs1057519879	GRCh37: 15:45003746-45003746 GRCh38: 15:44711548-44711548
44	RHOA	NM_001664.4(RHOA):c.125A>T (p.Tyr42Phe)	SNV	Likely Pathogenic	376524	rs1057519954	GRCh37: 3:49412898-49412898 GRCh38: 3:49375465-49375465
45	B2M	NM_004048.4(B2M):c.1A>G (p.Met1Val)	SNV	Likely Pathogenic	376369	rs1023835002	GRCh37: 15:45003745-45003745 GRCh38: 15:44711547-44711547
46	B2M	NM_004048.4(B2M):c.1A>T (p.Met1Leu)	SNV	Likely Pathogenic	376370	rs1023835002	GRCh37: 15:45003745-45003745 GRCh38: 15:44711547-44711547
47	MAP2K1	NM_002755.4(MAP2K1):c.170A>C (p.Lys57Thr)	SNV	Likely Pathogenic	376448	rs1057519909	GRCh37: 15:66727454-66727454 GRCh38: 15:66435116-66435116
48	RHOA	NM_001664.4(RHOA):c.125A>G (p.Tyr42Cys)	SNV	Likely Pathogenic	376522	rs1057519954	GRCh37: 3:49412898-49412898 GRCh38: 3:49375465-49375465
49	RHOA	NM_001664.4(RHOA):c.14G>A (p.Arg5Gln)	SNV	Likely Pathogenic	376520	rs1057519953	GRCh37: 3:49413009-49413009 GRCh38: 3:49375576-49375576
50	NRAS	NM_002524.5(NRAS):c.37G>C (p.Gly13Arg)	SNV	Likely Pathogenic	13899	rs121434595	GRCh37: 1:115258745-115258745 GRCh38: 1:114716124-114716124

UniProtKB/Swiss-Prot genetic disease variations for Lymphoma, Non-Hodgkin, Familial:

⁷³

#	Symbol	AA change	Variation ID	SNP ID
1	BRAF	p.Gly469Ala	VAR_018620	rs121913355
2	BRAF	p.Gly469Arg	VAR_018622	rs121913357
3	BRAF	p.Asp594Gly	VAR_018624	rs121913338
4	CASP10	p.Ala414Val	VAR_037430	rs28936699

Copy number variations for Lymphoma, Non-Hodgkin, Familial from CNVD:

⁶

#	CNVD ID	Chromosome	Start	End	Type	Gene Symbol	CNVD Disease
1	164351	22	36286416	36295356	Translate	CNTRL	Non-Hodgkin''s lymphomas

Sources

Expression for Lymphoma, Non-Hodgkin, Familial

Search GEO for disease gene expression data for Lymphoma, Non-Hodgkin, Familial.

Sources

Pathways for Lymphoma, Non-Hodgkin, Familial

Pathways related to Lymphoma, Non-Hodgkin, Familial according to GeneCards Suite gene sharing:

(show top 50) (show all 106)

#	Super pathways	Score	Top Affiliating Genes
1	Innate Immune System ⁶⁶ Show member pathways Immune System ⁶⁶ Neutrophil degranulation ⁶⁶	13.95	TP53 TNFRSF8 RHOA PIK3CA NRAS MYD88
2	ERK Signaling ⁶⁴ Show member pathways ILK Signaling ⁶⁴ MAPK Signaling ⁶⁴ Molecular Mechanisms of Cancer ⁶⁴ Rho Family GTPases ⁶⁴	13.88	TP53 TNFRSF8 RHOA NRAS MYC MAP2K1
3	Disease ⁶⁶ Show member pathways Infectious disease ⁶⁶	13.86	B2M BRAF EZH2 MAP2K1 MYC MYD88
4	Signal Transduction ⁶⁶	13.81	TP53 RHOA PIK3CA NRAS MYD88 MYC
5	GPCR Pathway ⁶⁴ Show member pathways Breast Cancer Regulation by Stathmin1 ⁶⁴ Estrogen Pathway ⁶⁴ NFAT in Immune Response ⁶⁴ P2Y Receptor Signaling ⁶⁴ Pancreatic Adenocarcinoma ⁶⁴ Paxillin Interactions ⁶⁴ Ras Pathway ⁶⁴	13.76	TP53 RHOA NRAS MYC MAP2K1 BRAF
6	MIF Mediated Glucocorticoid Regulation ⁶⁴ Show member pathways all-trans-Retinoic Acid Signaling in Brain ⁶⁴ Endothelin-1 Signaling Pathway ⁶⁴ Glucocorticoid Receptor Signaling ⁶⁴ IL-6 Pathway ⁶⁴ MIF Regulation of Innate Immune Cells ⁶⁴ NFAT Signaling and Lymphocyte Interactions ⁶⁴ Overview of proinflammatory and profibrotic mediators ⁷⁴ PEDF Induced Signaling ⁶⁴ PGC1Alpha Pathway ⁶⁴ RAR-Gamma-RXR-Alpha Degradation ⁶⁴ STAT3 Pathway ⁶⁴	13.69	TP53 TNFRSF8 NRAS MYC MAP2K1 CASP10
7	TGF-Beta Pathway ⁶⁴ Show member pathways JAK-STAT Pathway ⁶⁴ JNK Pathway ⁶⁴ MAPK Family Pathway ⁶⁴ Regulation of eIF4 and p70S6K ⁶⁴ SOCS Pathway ⁶⁴	13.6	TP53 RHOA PIK3CA NRAS MYC MAP2K1
8	Prolactin Signaling ⁶⁴ Show member pathways Development Prolactin receptor signaling ²² EGFR Inhibitor Pathway, Pharmacodynamics ⁶⁰ EGFR tyrosine kinase inhibitor resistance ⁷⁴ ErbB Family Pathway ⁶⁴ ErbB signaling pathway ⁷⁴ ErbB2-ErbB3 Heterodimers ⁶⁴ ErbB4 Pathway ⁶⁴ Estrogen-stimulated signaling through PRKCZ ⁶⁶ Glioblastoma Multiforme ⁶⁴ Glioblastoma signaling pathways ⁷⁴ Growth Hormone Signaling ⁶⁴ HMGB1 Pathway ⁶⁴ IL-2 Pathway ⁶⁴ LPS Stimulated MAPK Signaling ⁶⁴ PACAP Signaling ⁶⁴ PI3K Signaling in B-Lymphocyte ⁶⁴ TCA cycle nutrient use and invasiveness of ovarian cancer ⁷⁴ Thrombopoietin Pathway ⁶⁴ TREM1 Pathway ⁶⁴ UVA-Induced MAPK Signaling ⁶⁴ UVB-Induced MAPK Signaling ⁶⁴ UVC-Induced MAPK Signaling ⁶⁴	13.48	TP53 RHOA PIK3CA NRAS MYD88 MYC
9	Cytokine Signaling in Immune system ⁶⁶ Show member pathways Signaling by Interleukins ⁶⁶	13.08	B2M BCL2 BCL6 IRF4 MAP2K1 MYC
10	PI3K-Akt signaling pathway ⁷⁴ Show member pathways Focal adhesion: PI3K-Akt-mTOR-signaling pathway ⁷⁴	13.01	TP53 PIK3CA NRAS MYC MAP2K1 BCL2
11	NFAT and Cardiac Hypertrophy ⁶⁴ Show member pathways IGF1R Signaling ⁶⁴ Signaling Involved in Cardiac Hypertrophy ⁶⁴	12.92	RHOA PIK3CA NRAS MAP2K1 BRAF
12	IL-9 Signaling Pathways ⁶⁵ Show member pathways Adipocytokines and Insulin Signaling ⁶⁵ Common Cytokine Receptor Gamma-Chain Family Signaling Pathways ⁶⁵ Development Thrombopoietin-regulated cell processes ²² IL-15 Signaling Pathways ⁶⁵ IL-2 Signaling Pathways ⁶⁵ IL-21 Signaling Pathways ⁶⁵ IL-4 Pathway ⁶⁴ IL-4 Signaling Pathways ⁶⁵ IL-7 Signaling Pathways ⁶⁵ IL-9 Pathway ⁶⁴ Immune response IL-9 signaling pathway ²² Interleukin-9 signaling ⁶⁶	12.92	PIK3CA NRAS MYC MAP2K1 BRAF BCL2
13	CCR5 Pathway in Macrophages ⁶⁴ Show member pathways Androgen Signaling ⁶⁴ Chemokine Signaling ⁶⁴ Chemokine signaling pathway ⁷⁴	12.91	RHOA PIK3CA NRAS MAP2K1 BRAF
14	TNFR1 Pathway ⁶⁴ Show member pathways Apoptosis ⁷⁴ Apoptosis and survival TNFR1 signaling pathway ²² Apoptosis modulation by HSP70 ⁷⁴ Apoptosis through Death Receptors ⁶⁴ Apoptotic Pathways Triggered By HIV1 ⁶⁴ Ceramide signaling pathway ⁶¹ DR3 Signaling ⁶⁴ GITR Pathway ⁶⁴ HIV-1 Nef: Negative effector of Fas and TNF-alpha ⁶¹ Stimulation of the cell death response by PAK-2p34 ⁶⁶ TNF Signaling ⁶⁴ TNF-related weak inducer of apoptosis (TWEAK) signaling pathway ⁷⁴ TRAIL Pathway ⁶⁴ TWEAK Pathway ⁶⁴	12.9	TP53 RHOA PRF1 PIK3CA MYC MAP2K1
15	Signaling by Receptor Tyrosine Kinases ⁶⁶	12.89	RHOA PIK3CA NRAS MYC MAP2K1 BRAF
16	MAPK-Erk Pathway ⁶⁷ Show member pathways Actin Dynamics Signaling Pathway ⁶⁷ G Protein-coupled Receptors Signaling ⁶⁷	12.8	BRAF MAP2K1 NRAS PIK3CA RHOA
17	Malignant pleural mesothelioma ⁷⁴	12.75	TP53 PIK3CA MYC MAP2K1 EZH2 BCL2
18	Overview of interferons-mediated signaling pathway ⁷⁴ Show member pathways all-trans-Retinoic Acid Mediated Apoptosis ⁶⁴ Cytokine Network ⁶⁴ Immune response IFN alpha/beta signaling pathway ²² Interferon alpha/beta signaling ⁶⁶ Jak/STAT Signaling Pathway ⁶⁵ Regulation of IFNA/IFNB signaling ⁶⁶ Type III interferon signaling ⁷⁴	12.69	IRF4 MAP2K1 MYC NRAS PIK3CA TP53
19	TNF Superfamily - Human Ligand-Receptor Interactions and their Associated Functions ⁶⁵ Show member pathways 14-3-3 Induced Apoptosis ⁶⁴ TNF Superfamily Pathway ⁶⁴ TNFs bind their physiological receptors ⁶⁶ TRAF Pathway ⁶⁴	12.68	TNFRSF8 MYD88 MAP2K1 CASP10 BCL2
20	Immune response IL-23 signaling pathway ²² Show member pathways Angiopoietin receptor Tie2-mediated signaling ⁶¹ Angiopoietin-TIE2 Signaling ⁶⁴ Development Angiopoietin - Tie2 signaling ²² Development PDGF signaling via STATs and NF-kB ²² IL23-mediated signaling events ⁶¹ Immune response IL-10 signaling pathway ²² RAC1/PAK1/p38/MMP2 pathway ⁷⁴	12.65	BCL2 MYC NRAS PIK3CA TP53
21	Signaling by NTRKs ⁶⁶ Show member pathways Activated NTRK3 signals through PI3K ⁶⁶ Activated NTRK3 signals through PLCG1 ⁶⁶ Activated NTRK3 signals through RAS ⁶⁶ Activation of TRKA receptors ⁶⁶ NGF-independant TRKA activation ⁶⁶ NTF3 activates NTRK3 signaling ⁶⁶ NTRK3 as a dependence receptor ⁶⁶ PI3K/AKT activation ⁶⁶ Retrograde neurotrophin signalling ⁶⁶ Signaling by NTRK1 (TRKA) ⁶⁶ Signaling by NTRK3 (TRKC) ⁶⁶	12.62	RHOA PIK3CA NRAS MAP2K1 BRAF
22	NF-kappaB Signaling ³	12.62	TNFRSF8 MYD88 IRF4 BCL6 BCL10 B2M
23	Endometrial cancer ⁷⁴ Show member pathways Chromosomal and microsatellite instability in colorectal cancer ⁷⁴ Melanoma ⁷⁴ Non-small cell lung cancer ⁷⁴ Pancreatic adenocarcinoma pathway ⁷⁴ Signal transduction PTEN pathway ²²	12.59	TP53 RHOA PIK3CA NRAS MYC MAP2K1
24	Toll-like receptor signaling pathway ⁷⁴ Show member pathways Hepatitis B infection ⁷⁴ Measles virus infection ⁷⁴ Regulation of toll-like receptor signaling pathway ⁷⁴	12.54	TP53 PIK3CA NRAS MYD88 MYC MAP2K1
25	Hepatocyte growth factor receptor signaling ⁷⁴ Show member pathways Apoptosis and survival Anti-apoptotic action of membrane-bound ESR1 ²² Apoptosis and survival NGF signaling pathway ²² Apoptosis and survival Role of CDK5 in neuronal death and survival ²² Development HGF signaling pathway ²² Development Neurotrophin family signaling ²² Drug-mediated inhibition of MET activation ⁶⁶ MET activates PTPN11 ⁶⁶ MET activates STAT3 ⁶⁶ PLC-gamma1 signalling ⁶⁶ Trk receptor signaling mediated by PI3K and PLC-gamma ⁶¹ TRKA activation by NGF ⁶⁶	12.51	TP53 PIK3CA MAP2K1 BRAF BCL2
26	VEGF Pathway (Qiagen) ⁶⁴ Show member pathways CCKBR-Gastrin Stimulated Signaling ⁶⁴ Development VEGF-family signaling ²² Neurophilin interactions with VEGF and VEGFR ⁶⁶ VEGF and VEGFR signaling network ⁶¹ VEGF Family Ligands and Receptor Interactions ⁶⁴	12.5	RHOA PIK3CA NRAS MYD88 MAP2K1
27	Breast cancer pathway ⁷⁴ Show member pathways Embryonic stem cell pluripotency pathways ⁷⁴	12.48	BRAF MAP2K1 MYC NRAS PIK3CA TP53
28	Development Dopamine D2 receptor transactivation of EGFR ²² Show member pathways Chemotaxis CXCR4 signaling pathway ²² Development Alpha-2 adrenergic receptor activation of ERK ²² Extra-nuclear estrogen signaling ⁶⁶	12.47	RHOA PIK3CA NRAS MAP2K1 BCL2
29	Development VEGF signaling via VEGFR2 - generic cascades ²² Show member pathways Development VEGF signaling and activation ²² VEGF - VEGF R2 Signaling Pathways ⁶⁵	12.46	RHOA PIK3CA MAP2K1 BRAF
30	MAPK signaling pathway ⁷⁴	12.46	TP53 NRAS MYC MAP2K1 BRAF
31	NF-kappaB Pathway ⁷⁰ Show member pathways Akt Pathway ⁷⁰ Apoptosis Pathway ⁷⁰	12.46	TP53 PIK3CA NRAS MAP2K1 CASP10 BCL2
32	G-protein signaling RAC1 in cellular process ²² Show member pathways CDC42 signaling events ⁶¹ Cytoskeleton remodeling CDC42 in cellular processes ²² RAC1 signaling pathway ⁶¹	12.44	BRAF MAP2K1 NRAS PIK3CA RHOA
33	Death Receptor Signaling ⁶⁷ Show member pathways Apoptosis and survival Apoptotic TNF-family pathways ²² Apoptosis Signaling Pathway ⁶⁵ SARS-CoV-1-mediated effects on programmed cell death ⁶⁶ TNF Signaling ⁶⁷	12.42	TP53 MAP2K1 CASP10 BCL2
34	Apoptosis and Autophagy ³ Show member pathways Activation and oligomerization of BAK protein ⁶⁶ AIF Pathway ⁶⁴ Nanomaterial induced apoptosis ⁷⁴ Pro-survival signaling of neuroprotectin D1 ⁷⁴ vRNA Synthesis ⁶⁶	12.41	PRF1 MYC BCL2 BCL10
35	Apoptosis and survival FAS signaling cascades ²² Show member pathways Apoptosis and survival Caspase cascade ²² Breakdown of the nuclear lamina ⁶⁶ Caspase Cascade in Apoptosis ⁶¹ Fas ligand pathway and stress induction of heat shock proteins ⁷⁴ Fas Signaling ⁶⁴	12.4	PRF1 MAP2K1 CASP10 BCL2
36	Development A3 receptor signaling ²² Show member pathways Development A1 receptor signaling ²² G-protein signaling G-Protein alpha-q signaling cascades ²²	12.38	RHOA PIK3CA MYC MAP2K1
37	Toll Comparative Pathway ⁶⁴ Show member pathways IL-1 Pathway ⁶⁴ Immune response MIF in innate immunity response ²² iNOS Signaling ⁶⁴ TLR-TRIF Pathway ⁶⁴	12.37	TP53 PIK3CA MYD88 MAP2K1
38	B Cell Receptor Signaling Pathway ⁶⁷ Show member pathways T Cell Receptor Signaling Pathway ⁶⁷	12.37	PIK3CA NRAS MAP2K1 BCL6
39	Focal adhesion ⁷⁴	12.34	BCL2 BRAF MAP2K1 PIK3CA RHOA
40	PDGFR-beta signaling pathway ⁶¹ Show member pathways ErbB1 downstream signaling ⁶¹	12.33	RHOA PIK3CA MYC MAP2K1 BRAF
41	Development IGF-1 receptor signaling ²² Show member pathways Immune response IL-4 signaling pathway ²² Signal transduction AKT signaling ²²	12.32	TP53 PIK3CA MYC MAP2K1
42	Ras signaling ⁷⁴	12.3	MAP2K1 NRAS PIK3CA RHOA
43	GDNF-Family Ligands and Receptor Interactions ⁶⁴ Show member pathways BDNF Pathway ⁶⁴ Development GDNF family signaling ²²	12.26	PIK3CA NRAS MAP2K1 BCL2
44	Colorectal Cancer Metastasis ⁶⁴	12.25	TP53 MYC MAP2K1 BRAF
45	Epithelial to mesenchymal transition in colorectal cancer ⁷⁴	12.24	TP53 PIK3CA MAP2K1 EZH2
46	T-cell activation SARS-CoV-2 ⁷⁴ Show member pathways T-cell antigen receptor (TCR) pathway during Staphylococcus aureus infection ⁷⁴	12.2	BCL10 MAP2K1 MYD88 PIK3CA TP53
47	CCR3 Pathway in Eosinophils ⁶⁴ Show member pathways VEGF and S-1P Signaling ⁶⁴	12.19	RHOA NRAS MAP2K1 BRAF
48	Regulation of actin cytoskeleton ⁷⁴	12.19	RHOA PIK3CA NRAS MAP2K1 BRAF
49	NGF Pathway ⁶⁴ Show member pathways MAPK and NFkB signaling pathways inhibited by Yersinia YopJ ⁷⁴ TRKA Signaling ⁶⁴	12.19	TP53 RHOA NRAS MYC MAP2K1 BRAF
50	MAPK Signaling: Mitogens ⁶⁵ Show member pathways Akt Signaling Pathway ⁶⁵	12.19	TP53 PIK3CA NRAS MYC MAP2K1 BRAF

Sources

GO Terms for Lymphoma, Non-Hodgkin, Familial

Cellular components related to Lymphoma, Non-Hodgkin, Familial according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	protein-containing complex	GO:0032991	9.44	TP53 RAD54L MYD88 MYC CASP10 BCL2

Biological processes related to Lymphoma, Non-Hodgkin, Familial according to GeneCards Suite gene sharing:

(show all 18)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of apoptotic process	GO:0043065	10.27	TP53 TNFRSF8 BCL6 BCL2 BCL10
2	cellular response to DNA damage stimulus	GO:0006974	10.18	TP53 RAD54L RAD54B MYC BCL6 BCL2
3	MAPK cascade	GO:0000165	10.13	BRAF MAP2K1 MYC NRAS
4	positive regulation of cysteine-type endopeptidase activity involved in apoptotic process	GO:0043280	10.04	RHOA MYC BCL10
5	thymus development	GO:0048538	10.01	MAP2K1 BRAF BCL2
6	chromosome organization	GO:0051276	9.93	TP53 RAD54L MYC
7	regulation of gene expression	GO:0010468	9.92	PIK3CA MYD88 MYC FAS-AS1 EZH2 BCL2
8	response to gamma radiation	GO:0010332	9.91	BCL2 MYC TP53
9	response to amino acid	GO:0043200	9.88	RHOA MYD88 BCL2
10	determination of adult lifespan	GO:0008340	9.85	TP53 RAD54L RAD54B
11	B cell lineage commitment	GO:0002326	9.8	TP53 BCL2
12	regulation of cell population proliferation	GO:0042127	9.8	BCL6 BRAF EZH2 MYD88 TP53
13	regulation of axon regeneration	GO:0048679	9.72	MAP2K1 BRAF
14	positive regulation of protein serine/threonine kinase activity	GO:0071902	9.7	RHOA PIK3CA MAP2K1 EZH2
15	response to xenobiotic stimulus	GO:0009410	9.7	TP53 RHOA RAD54L RAD54B MYC BCL2
16	T cell lineage commitment	GO:0002360	9.69	TP53 BCL2
17	positive regulation of miRNA maturation	GO:1903800	9.56	TP53 MAP2K1
18	T cell differentiation in thymus	GO:0033077	9.23	TP53 BRAF BCL2 B2M